Dual antiplatelet therapy clopidogrel with low-dose cilostazol intensifies platelet inhibition in patients with ischemic stroke

Internal Medicine

Volumn 52, Issue 10, 2013, Pages 1043-1047

  Maruyama, Hajime ^a   Fukuoka, Takuya ^a   Deguchi, Ichiro ^a   Ohe, Yasuko ^a   Nagoya, Harumitsu ^a   Kato, Yuji ^a   Horiuchi, Yohsuke ^a   Hayashi, Takeshi ^a   Tanahashi, Norio ^a  

^a SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

Author keywords

Cilostazol; Clopidogrel resistance; Dual antiplatelet therapy; Ischemic stroke; Verifynow P2Y12 assay

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; FIBRINOGEN; PROTEINASE ACTIVATED RECEPTOR 4; PURINERGIC P2Y12 RECEPTOR;

AGED; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HEADACHE; HUMAN; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; TACHYCARDIA; THROMBOCYTE FUNCTION;

ADENOSINE DIPHOSPHATE; AGED; ARYL HYDROCARBON HYDROXYLASES; BRAIN ISCHEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2Y12; RISK FACTORS; TETRAZOLES; TICLOPIDINE;

EID: 84877849449     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.52.9550     Document Type: Article

References (20)

1. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 lossof-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108: 2244-2247, 2006.
2. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5: 2429-2436, 2007.
3. Kim KA, Park PW, Hong SJ, Park JY. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 84: 236-242, 2008.
4. Umemura K, Furuta T, Kondo K. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost 6: 1439-1441, 2008.
5. Jinnai T, Horiuchi H, Makiyama T, et al. Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan. Circ J 73: 1498-1503, 2009.
6. Maruyama H, Takeda H, Dembo T, et al. Clopidogrel resistance and the effect of combination cilostazol in patients with ischemic stroke or carotid artery stenting using the VerifyNow P2Y12 As say. Intern Med 50: 695-698, 2011.
7. Brar SS, ten Berg J, Marcucci R, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 58: 1945-1954, 2011.
8. Price MJ, Angiolillo DJ, Teirstein PS, et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 124: 1132-1137, 2011.
9. Ueno M, Ferreiro JL, Tomasello SD, et al. Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. J Am Coll Cardiol Intv 4: 905-912, 2011.
10. Kim JY, Lee K, Shin M, et al. Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. Circ J 71: 1867-1872, 2007.
11. Shim CY, Yoon SJ, Park S, et al. The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation. Int J Caidiol 134: 351-355, 2009.
12. Jin EZ, Yu LH, Li XQ. Loading effect of cilostazol 200 mg on platelet inhibition in patients undergoing percutaneous coronary intervention. Int Heart J 53: 1-4, 2012.
13. Jeong YH, Hwang JY, Kim IS, et al. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: result of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. Circ Cardiovasc Interv 3: 17-26, 2010.
14. Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: result of the ACCEL-RESISTANCE (adjunctive cilostazol versus high maintenance dose clopidogrel in patients with clopidogrel resistance) randomized study. J Am Coll Cardiol 53: 1101-1109, 2009.
15. Park KW, Park JJ, Lee SP, et al. Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial. Heart 97: 641-647, 2011.
16. Hwang SJ, Jeong YH, Kim IS, et al. Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 3: 450-459, 2010.
17. Yang TH, Kim DI, Kim DK, et al. Detection of clopidogrel hyporesponsiveness using a point-of-care assay and the impact of additional cilostazol administration after coronary stent implantation in diabetic patients. Korean J Intern Med 26: 145-152, 2011.
18. Lee JM, Park S, Shin DJ, et al. Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans. Am J Cardiol 104: 46-51, 2009.
19. Haraguchi K, Miyachi S, Izumi T, et al. Resistance to antiplatelet agents assessed by a point-of-care platelet function test and thromboembolic adverse events in neurointervention. No Shinkei Geka 40: 399-406, 2012 (in Japanese, Abstract in English).
20. Yamagami H, Sakai N, Matsumaru Y, et al. Periprocedural cilostazol treatment and restenosis after carotid artery stenting: the Retrospective Study of In-Stent Restenosis after Carotid Artery Stenting (ReSISteR-CAS). J Stroke Cerebrovasc Dis 21: 193-199, 2012.